Tag:
Anthera
Latest Headlines
Latest Headlines
Anthera slashes jobs over failed cardiac trial, shifts focus to lupus drug
Days after announcing it halted a late-stage Phase III trial of its lead drug over struggles to prove its efficacy, the company disclosed it will eliminate about 45% of its workforce.
Vial cracking causes halt in lupus drug trial
Cracked vials have led to the suspension of a clinical trial. Biotech drug developer Anthera found the cracks in vials of its experimental lupus drug, A-623, which is in Phase IIb testing. The
Cracked vials force Anthera ($ANTH) to suspend PhIIb lupus study
Hayward, CA-based Anthera Pharmaceuticals ( $ANTH ) announced this morning that it is suspending dosing and enrollment in a Phase IIb study of its experimental lupus drug after a clinical investigator
Anthera IPO limps out at half price
In an ominous display of financial weakness, Anthera Pharmaceuticals went public this morning, pricing its shares at half of what it had originally hoped for. Deutsche Bank says the IPO raised $32.2
Anthera delays IPO and sends a chilling message
Biotech companies eager to dust off their old IPO plans may want to wait awhile longer. Anthera Pharmaceuticals, a classic drug developer with high hopes and no steady income, opted to delay its
Anthera looks to raise $70M with IPO
Anthera has no sales or profit, but the company is hoping to raise almost $70 million in an IPO offering this week. It will be a true test of the market's appetite for risky investment. But, if
Can Anthera whet investors' appetite for biotech IPOs?
In a fresh sign that biotech IPOs have begun a long-awaited revival, Anthera Pharmaceuticals has filed to sell $70 million of shares in a new initial public offering. Talecris' move to launch its IPO
Anthera garners $19M in new venture funds
Anthera Pharmaceuticals has completed a $19 million venture round and plans to use the funds to advance its work on anti-inflammatory drugs. New investors Caxton Advantage Life Sciences Fund and HBM
